I specialize in design and analysis of experimental and observational studies, including individual- and community-randomized clinical trials, complex surveys, and epidemiological cohort studies. I integrate diverse data sources—from clinical and survey data to electronic health records—to infer population-level characteristics and generate real-world evidence. My methodological work focuses on missingness and non-random selection, including cases where missingness depends on unobserved data (missing not at random). I address these problems in the context of comparative effectiveness, causal inference, and population-level inference. My collaborative research spans population health in diverse biomedical and epidemiological domains, including infectious and chronic diseases, sexual health, and mental health, and how medical, social, and environmental factors affect health and well-being. Much of my research has focused on at risk and hard-to-reach populations, such as children, sexual and racial/ethnic minorities, and people living in rural communities, which involve challenges in recruitment, analysis and representation. Below are some representative publications. Please visit my Google Scholar page for a complete list.

Selected Methodological Research

  1. Meisner, A, Xia, F, Chan, KC, Mayer, K, Wheeler, D, Zangeneh, SZ, & Donnell, D (2025). Estimating the effect of pre-exposure prophylaxis in Black men who have sex with men. International Journal of Epidemiology, 54(1), dyae170.
  2. Zangeneh, SZ, Skalland, T, Yuhas, K, Emel, L, …, Justman, J (2024). Adaptive time location sampling for COMPASS, a SARS-COV-2 prevalence study in fifteen diverse communities in the United States. Epidemiology, 35(3), 389–397.
  3. Zangeneh, SZ & Little RJ (2022). Likelihood-based inference for the finite population mean with post-stratification information under non-ignorable non-response. International Statistics Review, 90, S17–S36.
  4. Little, RJ, Rubin, DB, & Zangeneh, SZ (2017). Conditions for ignoring the missing-data mechanism in likelihood inferences for parameter subsets. Journal of the American Statistical Association–Theory & Methods, 112(517), 314–320.
  5. Zangeneh, SZ & Little, RJ (2015). Bayesian inference for the finite population total from a heteroscedastic probability proportional to size sample. Journal of Survey Statistics and Methodology, 3(2), 162–192.

Selected Collaborative Research

  1. Dorner, RA, Li, L, DeMauro, SB, Schmidt, B, Zangeneh, SZ, …, Das, A (2025). Association of a count of inpatient morbidities with two-year outcomes among infants born extremely preterm. The Journal of Pediatrics, 114428.
  2. Gibbons, RD, Olfson, M, Saulsberry, L, Edlund, MJ, Zangeneh, SZ, ... & Kessler, RC (2024). Social vulnerability and prevalence and treatment for mental health and substance use disorders. JAMA Psychiatry, 81(10), 976–984.
  3. Justman, J, Skalland, T, Moore, A, Amos, CI, Marzinke, MA, Zangeneh, SZ, ..., CoVPN 5002 COMPASS Study Team (2024). Prevalence of SARS-CoV-2 infection among children and adults in 15 US communities, 2021. Emerging Infectious Diseases, 30(2), 245–254.
  4. Brooks-Worrell, B, Hampe, CS, Hattery, EG, Palomino, B, Zangeneh, SZ, Utzschneider, K, ... & GRADE Research Group (2022). Islet autoimmunity is highly prevalent and associated with diminished β-cell function in patients with type 2 diabetes in the GRADE study. Diabetes.
  5. Tordoff, DM*, Zangeneh, SZ, Khosropour, CM, Glick, SN, McClelland, RS, Dimitrov, D, ... & Duerr, A (2022). Geographic variation in HIV testing among transgender and non-binary adults in the US. Journal of Acquired Immune Deficiency Syndromes. (*Tordoff UW mentee of Zangeneh)
  6. Ogimi, C, Qu, P, Boeckh, M, Bender Ignacio, RA, & Zangeneh, SZ (2021). Association between live childhood vaccines and COVID-19 outcomes: A national-level analysis. Epidemiology and Infection, 149.
  7. Tapsoba, JDD*, Zangeneh, SZ*, Appelmans, E*, Pasalar, S, Mori, K, Peng, L, …, Mukabi, J (2021). Persistence of oral pre-exposure prophylaxis (PrEP) among adolescent girls and young women initiating PrEP for HIV prevention in Kenya. AIDS Care, 1–9. (*Joint first authors)
  8. Tolley, EE, Zangeneh, SZ, Chau, G, Eron, J, Grinsztejn, B, Humphries, H, …, Li, S (2020). Acceptability of long-acting injectable cabotegravir (CAB LA) in HIV-uninfected individuals: HPTN 077. AIDS and Behavior, 1–12.
  9. Landovitz, RJ, Zangeneh, SZ, Chau, G, Grinsztejn, B, Eron, JJ, Dawood, H, … Currier, JS (2019). Cabotegravir is not associated with weight gain in HIV-negative individuals: HPTN 077. Clinical Infectious Diseases.
  10. Chun, PT, McPherson, RJ, Marney, LC, Zangeneh, SZ, …, Juul, SE (2015). Serial plasma metabolites following hypoxic-ischemic encephalopathy in a nonhuman primate model. Developmental Neuroscience, 37(2), 161–171.